Header Mediar

We are applying a precision approach to our fibrosis programs to improve the odds of success in human proof-of-concept studies and identify the right patients for each therapy.

Rahul Ballal, Ph.D - CEO of Mediar Therapeutics


Mediar Therapeutics Inc. (Cambridge, MA, USA) was founded on pioneering fibrosis research from Mass General and Brigham & Women’s Hospitals in partnership with Mass General Brigham Ventures in 2018 with the goal to transform the treatment of fibrotic disease by targeting a key driver of disease progression, a recently discovered cell type called the Myofibroblast.
Mediar, advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, raised a $105M financing in 2022, including an $85 million Series A financing co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Gimv, Pfizer Ventures, Mission BioCapital, Pureos, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, and Mass General Brigham Ventures. 

Icon entry


Icon employees


Icon location


When ambition meets ambition

Fibrosis, directly and indirectly, contributes to 45 percent of deaths in the industrialized world and is among the most complicated chronic pathologies due to an expansive and complex network of interwoven biological pathways. Fibrosis is often a vicious, self-enforcing cycle causing damage long past the resolution of its initial cause.

Existing therapies mainly focus on the body's own response to fibrosis, by inhibiting an over-active immune system. However, these interventions lead to severe side effects since the body relies on a functional immune system to fight off pathogens. Mediar focuses on stopping and even reversing this destructive cycle by targeting fibrosis-specific drivers of progression. 

Together, we build a leading company

Mediar’s portfolio comprises novel targets that are readily detectible in blood and correlate to disease severity, enabling a de-risked approach to clinical development. The financing will support advancement of the company’s portfolio of first-in-class antibody treatments, which offer unique potential to address fibrosis at varying stages of the disease.

Deep research insights and a robust understanding of fibrotic disease, coupled with a focus on pursuing unexplored pathways that drive fibrosis progression, position Mediar to change the way the disease is addressed and potentially achieve meaningful therapeutic impact.


Pioneering therapies to halt and revert Fibrosis
17 FTE